Zacks Research Predicts Novavax’s Q3 Earnings (NASDAQ:NVAX)

Novavax, Inc. (NASDAQ:NVAX) – Investment analysts at Zacks Research raised their Q3 2027 earnings estimates for shares of Novavax in a report released on Tuesday, July 7th. Zacks Research analyst Team now anticipates that the biopharmaceutical company will earn $0.09 per share for the quarter, up from their prior forecast of $0.08. Zacks Research has a “Strong-Buy” rating on the stock. The consensus estimate for Novavax’s current full-year earnings is ($0.19) per share. Zacks Research also issued estimates for Novavax’s Q4 2027 earnings at $0.17 EPS, Q1 2028 earnings at $0.08 EPS, Q2 2028 earnings at $0.08 EPS and FY2028 earnings at $1.41 EPS.

Novavax (NASDAQ:NVAX) last released its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.19. The firm had revenue of $118.90 million for the quarter, compared to analysts’ expectations of $79.81 million. Novavax had a negative net margin of 14.73% and a negative return on equity of 14.82%. The company’s revenue for the quarter was down 79.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.93 earnings per share.

Several other research firms have also recently issued reports on NVAX. Weiss Ratings cut Novavax from a “hold (c-)” rating to a “sell (d)” rating in a research note on Thursday, May 7th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Novavax in a research report on Thursday, March 12th. BTIG Research reaffirmed a “buy” rating and set a $19.00 target price on shares of Novavax in a research note on Thursday, June 11th. TD Cowen boosted their price target on shares of Novavax from $8.00 to $9.00 and gave the company a “hold” rating in a research report on Wednesday, May 6th. Finally, Wall Street Zen raised shares of Novavax from a “sell” rating to a “hold” rating in a research note on Sunday, May 31st. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $13.00.

Novavax Price Performance

NVAX opened at $9.46 on Wednesday. Novavax has a one year low of $6.20 and a one year high of $11.97. The business has a 50 day simple moving average of $9.28 and a two-hundred day simple moving average of $8.86. The firm has a market capitalization of $1.56 billion, a price-to-earnings ratio of -16.31 and a beta of 2.43.

Hedge Funds Weigh In On Novavax

Several large investors have recently modified their holdings of NVAX. Edgestream Partners L.P. purchased a new position in Novavax in the 1st quarter worth about $4,234,000. California State Teachers Retirement System grew its stake in shares of Novavax by 39.9% in the first quarter. California State Teachers Retirement System now owns 186,638 shares of the biopharmaceutical company’s stock worth $1,519,000 after acquiring an additional 53,234 shares during the period. Quantinno Capital Management LP raised its holdings in shares of Novavax by 53.4% during the first quarter. Quantinno Capital Management LP now owns 35,359 shares of the biopharmaceutical company’s stock valued at $288,000 after purchasing an additional 12,304 shares during the last quarter. Renaissance Technologies LLC purchased a new position in shares of Novavax during the first quarter valued at approximately $4,049,000. Finally, Caxton Associates LLP bought a new position in Novavax during the first quarter valued at approximately $90,000. Hedge funds and other institutional investors own 53.04% of the company’s stock.

Key Novavax News

Here are the key news stories impacting Novavax this week:

• Positive Sentiment: Zacks Research upgraded Novavax to strong-buy, signaling improved analyst confidence in the stock. Zacks upgrade
• Positive Sentiment: Analysts raised EPS estimates for several upcoming periods, including FY2028 EPS to $1.41 from $1.29, implying a stronger earnings outlook. Zacks estimate increases
• Neutral Sentiment: Novavax has been identified as a trending stock, which may be contributing to trading interest but does not by itself change fundamentals. Trending stock article

Novavax Company Profile

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.